A Bayesian meta-analysis of transcatheter versus surgical aortic valve replacement in patients with small aortic annulus.

IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Vinícius Martins Rodrigues Oliveira, Maria Elisa Passos Nishikubo, Ana Gabrielly Oliveira Antunes, Lucas M Barbosa, Pedro Antônio de Sousa, Lucca Lopes, Ludimilla Pereira Tartuce, Daniela do Carmo Rassi, Humberto Graner Moreira
{"title":"A Bayesian meta-analysis of transcatheter versus surgical aortic valve replacement in patients with small aortic annulus.","authors":"Vinícius Martins Rodrigues Oliveira, Maria Elisa Passos Nishikubo, Ana Gabrielly Oliveira Antunes, Lucas M Barbosa, Pedro Antônio de Sousa, Lucca Lopes, Ludimilla Pereira Tartuce, Daniela do Carmo Rassi, Humberto Graner Moreira","doi":"10.1016/j.carrev.2025.09.011","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Small aortic annulus (SAA) is associated to suboptimal results after aortic valve replacement. The optimal treatment for aortic disease in SAA remains unclear.</p><p><strong>Methods: </strong>We conducted a systematic review and Bayesian random-effects meta-analysis to compare transcatheter (TAVR) versus surgical aortic valve replacement (SAVR) in patients with small aortic annulus. A comprehensive search of PubMed, Scopus, and Cochrane Library was performed through May 2024. Binary outcomes were synthesized using a binomial-normal hierarchical model to estimate posterior distributions of log odds ratios (log OR) and corresponding 95 % credible intervals (CrIs). Posterior probabilities of treatment effects were calculated to assess the certainty of benefit or harm. All statistical analyses were performed using R version 4.5.0.</p><p><strong>Results: </strong>Nine studies comprising 2548 patients (50.9 % TAVR) were included. TAVR was associated with reduced risk of severe patient-prosthesis mismatch (OR 0.47; 95 % CrI 0.31-0.72; posterior probability of benefit 99.8 %) and moderate mismatch (OR 0.56; 95 % CrI 0.40-0.79; posterior probability 99.7 %). In contrast, SAVR was associated with lower risk of moderate/severe aortic regurgitation (OR 4.74; 95 % CrI 2.43-9.27; posterior probability of harm with TAVR 98.1 %) and permanent pacemaker implantation (OR 2.66; 95 % CrI 1.69-4.20; posterior probability of harm with TAVR 98.5 %). No meaningful differences were observed for stroke at 30 days (OR 1.51; 95 % CrI 0.69-3.36) or all-cause mortality at 1 year (OR 0.78; 95 % CrI 0.51-1.17).</p><p><strong>Conclusions: </strong>TAVR is superior to SAVR regarding severe and moderate PPM in SAA patients. SAVR is associated with lower risk of aortic regurgitation and new pacemaker implant, with no significant differences in mortality and stroke.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.carrev.2025.09.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Small aortic annulus (SAA) is associated to suboptimal results after aortic valve replacement. The optimal treatment for aortic disease in SAA remains unclear.

Methods: We conducted a systematic review and Bayesian random-effects meta-analysis to compare transcatheter (TAVR) versus surgical aortic valve replacement (SAVR) in patients with small aortic annulus. A comprehensive search of PubMed, Scopus, and Cochrane Library was performed through May 2024. Binary outcomes were synthesized using a binomial-normal hierarchical model to estimate posterior distributions of log odds ratios (log OR) and corresponding 95 % credible intervals (CrIs). Posterior probabilities of treatment effects were calculated to assess the certainty of benefit or harm. All statistical analyses were performed using R version 4.5.0.

Results: Nine studies comprising 2548 patients (50.9 % TAVR) were included. TAVR was associated with reduced risk of severe patient-prosthesis mismatch (OR 0.47; 95 % CrI 0.31-0.72; posterior probability of benefit 99.8 %) and moderate mismatch (OR 0.56; 95 % CrI 0.40-0.79; posterior probability 99.7 %). In contrast, SAVR was associated with lower risk of moderate/severe aortic regurgitation (OR 4.74; 95 % CrI 2.43-9.27; posterior probability of harm with TAVR 98.1 %) and permanent pacemaker implantation (OR 2.66; 95 % CrI 1.69-4.20; posterior probability of harm with TAVR 98.5 %). No meaningful differences were observed for stroke at 30 days (OR 1.51; 95 % CrI 0.69-3.36) or all-cause mortality at 1 year (OR 0.78; 95 % CrI 0.51-1.17).

Conclusions: TAVR is superior to SAVR regarding severe and moderate PPM in SAA patients. SAVR is associated with lower risk of aortic regurgitation and new pacemaker implant, with no significant differences in mortality and stroke.

小主动脉环患者经导管与手术主动脉瓣置换术的贝叶斯荟萃分析。
背景:主动脉环小(SAA)与主动脉瓣置换术后的次优结果相关。SAA主动脉疾病的最佳治疗方法尚不清楚。方法:我们进行了一项系统综述和贝叶斯随机效应荟萃分析,比较经导管(TAVR)和手术主动脉瓣置换术(SAVR)对小主动脉环患者的影响。对PubMed, Scopus和Cochrane图书馆进行了全面的搜索,直到2024年5月。使用二项-正态分层模型合成二元结果,以估计对数比值比(log OR)的后验分布和相应的95%可信区间(CrIs)。计算治疗效果的后验概率以评估益处或危害的确定性。所有统计分析均使用R 4.5.0版本进行。结果:纳入9项研究,共2548例患者(TAVR为50.9%)。TAVR与严重患者-假体不匹配(OR 0.47; 95% CrI 0.31-0.72;获益后验概率99.8%)和中度不匹配(OR 0.56; 95% CrI 0.40-0.79;后验概率99.7%)的风险降低相关。相比之下,SAVR与中/重度主动脉瓣反流(OR 4.74; 95% CrI 2.43-9.27; TAVR后验伤害概率为98.1%)和永久性起搏器植入(OR 2.66; 95% CrI 1.69-4.20; TAVR后验伤害概率为98.5%)的风险较低相关。30天卒中(OR 1.51; 95% CrI 0.69-3.36)或1年全因死亡率(OR 0.78; 95% CrI 0.51-1.17)无显著差异。结论:对于SAA患者的重度和中度PPM, TAVR优于SAVR。SAVR与主动脉反流和新起搏器植入的风险较低相关,在死亡率和卒中方面无显著差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiovascular Revascularization Medicine
Cardiovascular Revascularization Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.30
自引率
5.90%
发文量
687
审稿时长
36 days
期刊介绍: Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. Cardiovascular Revascularization Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell therapy, pharmacological interventions, restenosis management, and prevention, including experiments conducted in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信